Quote:
Ph1 dose escalation study. While a small study, and one designed to test dose escalation tolerance, not disease impact, one might have wished to see more disease impact:
First my apologies for the late reply, I am not logging in every day nor watching the stock up and downs on a daily basis.
Meishairwin, I am well aware that the size is small, I was just trying to point out that there is disease impact and even with a small study the hypothesis on Lm platform holds.
For the Lm platform to make its magic it is needed more than one dose and time.
The small study can not confirm nor debunk statistically the hypothesis, however I feel ok with the results so far when comparing the results between population with one dose and two doses.
If we add that the patients on this trial already went through a round of treatment ... then things do look better at least for me.
any way it is what it is .. this is just another piece of the puzzle.
Go Zen
Cheers
News 
Market Data 
Discover 
